David Kallend Selected Research

David Kallend Research Topics

Disease

12	Coronary Disease (Coronary Heart Disease) 01/2020 - 04/2004
9	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 07/2009
9	Acute Coronary Syndrome 01/2020 - 12/2009
6	Inflammation (Inflammations) 01/2021 - 01/2011
3	Type 2 Diabetes Mellitus (MODY) 01/2020 - 04/2004
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2018 - 04/2005
3	Atherosclerotic Plaque (Atheroma) 01/2018 - 08/2011
3	Myocardial Infarction 10/2017 - 11/2012
3	Atherosclerosis 01/2017 - 04/2004
2	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020 - 11/2018
2	Hypertension (High Blood Pressure) 06/2015 - 07/2009
2	Unstable Angina 06/2015 - 11/2012
2	Hypercholesterolemia 10/2004 - 05/2004
1	Liver Diseases (Liver Disease) 03/2022
1	Necrosis 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Homozygous Familial Hypercholesterolemia 01/2020
1	Prediabetic State (Prediabetes) 01/2020
1	Dyslipidemias (Dyslipidemia) 01/2019
1	Heart Failure 10/2017
1	Left Ventricular Dysfunction 10/2017
1	Arteritis 01/2017
1	Injection Site Reaction 01/2017
1	Vascular Calcification 01/2016
1	Stroke (Strokes) 06/2015
1	Myocardial Ischemia (Ischemic Heart Diseases) 06/2015
1	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 12/2014
1	Hypoalphalipoproteinemias (Hypoalphalipoproteinemia) 12/2014
1	Heart Arrest (Cardiac Arrest) 11/2012
1	Ischemic Stroke 11/2012

Drug/Important Bio-Agent (IBA)

14	dalcetrapibIBA 01/2020 - 07/2009
7	ALN-PCSIBA 03/2022 - 01/2017
7	LDL CholesterolIBA 01/2020 - 05/2004
7	Cholesterol Ester Transfer ProteinsIBA 01/2020 - 07/2009
7	LipidsIBA 12/2016 - 10/2004
5	HDL CholesterolIBA 01/2020 - 02/2010
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 06/2015
4	HDL LipoproteinsIBA 01/2020 - 11/2012
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2012
3	Small Interfering RNA (siRNA)IBA 01/2021 - 01/2019
3	Lipoproteins (Lipoprotein)IBA 12/2016 - 07/2014
3	Rosuvastatin Calcium (Crestor)FDA Link 10/2004 - 04/2004
2	oxidized low density lipoproteinIBA 01/2021 - 01/2019
2	MDCO-216IBA 01/2018 - 12/2016
2	Atorvastatin (Lipitor)FDA Link 06/2015 - 04/2004
2	Triglycerides (Triacylglycerol)IBA 06/2015 - 05/2004
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Antisense OligonucleotidesIBA 01/2021
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020
1	Proprotein Convertase 9IBA 01/2020
1	omega-Chloroacetophenone (Mace)IBA 01/2020
1	SodiumIBA 01/2020
1	apolipoprotein A-I MilanoIBA 01/2018
1	Lipoprotein(a)IBA 01/2018
1	AldosteroneIBA 10/2017
1	Mineralocorticoid Receptor AntagonistsIBA 10/2017
1	Apolipoproteins AIBA 12/2016
1	CholesterolIBA 06/2015
1	Phytosterols (Plant Sterols)IBA 12/2014
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 12/2014
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 12/2014
1	ApolipoproteinsIBA 07/2014
1	Peroxidase (Myeloperoxidase)IBA 10/2013
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2012
1	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 04/2012
1	torcetrapibIBA 07/2009
1	Fenofibrate (CiL)FDA LinkGeneric 05/2004
1	Simvastatin (Zocor)FDA LinkGeneric 04/2004
1	Pravastatin (Pravachol)FDA LinkGeneric 04/2004

Therapy/Procedure

8	Therapeutics 01/2021 - 12/2009
2	Subcutaneous Injections 01/2020 - 01/2017
1	Intravenous Infusions 01/2018
1	Injections 01/2017
1	Resuscitation 11/2012
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 10/2004